Agenus Inc (AGEN)
Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
AGEN SEC Filing Email Alerts Service
| Company Name: |
Agenus Inc |
| Website: |
www.agenusbio.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding AGEN: |
16 |
| Total Market Value Held by ETFs: |
$96.33M |
| Total Market Capitalization: |
$2.40B |
| % of Market Cap. Held by ETFs: |
4.01% |
|
|
April 20, 2024 • 4:34 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free AGEN Email Alerts:
